Disease on EC 1.14.11.29 - hypoxia-inducible factor-proline dioxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Kidney Injury
Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury.
Adenocarcinoma
Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand.
Adenoma, Oxyphilic
Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated ELGN2-mediated oxygen-sensing response.
Altitude Sickness
EPAS1 and EGLN1 associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau.
Variants of the low oxygen sensors EGLN1 and HIF-1AN associated with acute mountain sickness.
Anemia
A mechanistic link between renal ischemia and fibrosis.
American chemical society - 239th national meeting - investigating new therapeutic candidates: part 2.
Anemia in conventional hemodialysis: Finding the optimal treatment balance.
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
First-in-man / proof of concept study with molidustat - a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
HIF prolyl hydroxylase inhibitors for anemia.
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury.
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
Aneurysm
Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Recoupling of eNOS with folic acid prevents abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E null mice.
Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid.
Suppression of abdominal aortic aneurysm formation by inhibition of prolyl hydroxylase domain protein through attenuation of inflammation and extracellular matrix disruption.
Atherosclerosis
Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia.
Autoimmune Diseases
American chemical society - 239th national meeting - investigating new therapeutic candidates: part 2.
Bone Resorption
Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2.
Brain Injuries
Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia.
Breast Neoplasms
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Detection of a 4-bp Insertion/deletion Polymorphism within the Promoter of EGLN2 Using Mismatch PCR-RFLP and Its Association with Susceptibility to Breast Cancer
DNA methylation analysis of the HIF-1? prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas.
EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer.
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
EglN2 positively regulates mitochondrial function in breast cancer.
Hypoxia represses microRNA biogenesis proteins in breast cancer cells.
Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer.
Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-?1 processing.
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.
Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.
Carcinogenesis
Association of chromosome 19 to lung cancer genotypes and phenotypes.
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer.
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
EglN2 positively regulates mitochondrial function in breast cancer.
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.
Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells.
Carcinoma
An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand.
iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells.
Carcinoma, Hepatocellular
Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo.
Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.
Carcinoma, Renal Cell
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Choroidal Neovascularization
Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization.
Colitis
Hypoxia and gastrointestinal disease.
Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function.
N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant.
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis.
Colorectal Neoplasms
An insertion/deletion polymorphism within the promoter of EGLN2 is associated with susceptibility to colorectal cancer.
Dystonia
Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice.
Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse.
GCH1 variants, tetrahydrobiopterin and their effects on pain sensitivity.
Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse.
Empyema
Necrotizing pneumonia and empyema in an immunocompetent patient caused by Nocardia cyriacigeorgica and identified by 16S rRNA and secA1 sequencing.
Endometrial Neoplasms
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Gastroparesis
In vivo ultrasound assessment of gastric emptying in newborn mice.
Glioblastoma
Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-?.
Glioma
Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD.
Glucose Intolerance
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Granuloma
Mycobacterium marinum SecA2 Promotes Stable Granulomas and Induces Tumor Necrosis Factor Alpha In Vivo.
gtp cyclohydrolase i deficiency
GTP cyclohydrolase I expression, protein, and activity determine intracellular tetrahydrobiopterin levels, independent of GTP cyclohydrolase feedback regulatory protein expression.
Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse.
Herpes Simplex
Antiviral activities against herpes simplex virus type 1 by HPH derivatives and their structure-activity relationships.
Hyperglycemia
Elevating VEGF-A and PDGF-BB secretion by salidroside enhances neoangiogenesis in diabetic hind-limb ischemia.
ROS- and HIF1?-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis.
Hypertension
GTP cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and thrombospondin-1 in salt-sensitive hypertension.
Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse.
Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid.
[Correlation between EGLN1 gene, protein express in lung tissue of rats and pulmonary artery pressure at different altitude].
Hypertension, Pulmonary
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.
Prolyl Hydroxylase Domain-2 Protein Regulates Lipopolysaccharide-Induced Vascular Inflammation.
Pulmonary hypertension in the newborn GTP cyclohydrolase I-deficient mouse.
hypoxia-inducible factor-proline dioxygenase deficiency
Neuronal prolyl-4-hydroxylase 2 deficiency improves cognitive abilities in a murine model of cerebral hypoperfusion.
Tetrahydrobiopterin (BH
Infection
Tsukamurella pulmonis bloodstream infection identified by secA1 gene sequencing.
Insulin Resistance
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Ischemic Attack, Transient
Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia.
Kidney Diseases
?-Ketoglutarate-related inhibitors of HIF prolyl hydroxylases are substrates of renal organic anion transporters 1 (OAT1) and 4 (OAT4).
Inhibitors of oxygen sensing prolyl hydroxylases regulate nuclear localization of the transcription factors Smad2 and YAP/TAZ involved in CTGF synthesis.
Liver Diseases
Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis.
Liver Neoplasms
Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.
Lung Neoplasms
Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer.
The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.
Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.
Melanoma
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.
Monoclonal Gammopathy of Undetermined Significance
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Multiple Myeloma
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Myocardial Infarction
Targeted Gene deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis And Preserves Cardiac Function by stabilizing Hypoxia inducible Factor 1 Alpha Following Myocardial Infarction.
Nasopharyngeal Neoplasms
Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene.
Neoplasm Metastasis
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.
Hypoxia-inducible factors as key regulators of tumor inflammation.
Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
Thermal unfolding pathway of PHD2 catalytic domain in three different PHD2 species: computational approaches.
Neoplasms
A New Role for PHD in Chemotherapy.
An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation.
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer.
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.
Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo.
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.
Exposure to cigarette smoke induces overexpression of von Hippel-Lindau tumor suppressor in mouse skeletal muscle.
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.
HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGF? activation.
HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.
Hypoxia Exacerbates Inflammatory Acute Lung Injury via the Toll-Like Receptor 4 Signaling Pathway.
Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
Hypoxia-inducible factors as key regulators of tumor inflammation.
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Induction of plasminogen activator inhibitor I gene expression by intracellular calcium via hypoxia-inducible factor-1.
Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Anti-Proliferative Activity of Transforming Growth Factor{beta}
Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression.
Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-?1 processing.
Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
Mycobacterium marinum SecA2 Promotes Stable Granulomas and Induces Tumor Necrosis Factor Alpha In Vivo.
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors.
Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.
PHD2 mutation and congenital erythrocytosis with paraganglioma.
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism.
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism.
Prolyl hydroxylase-2 inhibits liver tumor cell proliferation and cyclin D1 expression in a hydroxylase-dependent manner.
Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.
Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4.
Regulation of IL-1?-induced NF-?B by hydroxylases links key hypoxic and inflammatory signaling pathways.
Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
The role of HIF prolyl hydroxylases in tumor growth.
The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Neurofibromatoses
Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches.
Non-alcoholic Fatty Liver Disease
Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis.
Obesity
HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction.
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Pancreatic Neoplasms
Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1?.
Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer.
Paraganglioma
Modeling dioxygenase enzyme kinetics in familial paraganglioma.
Paraganglioma, Extra-Adrenal
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
Paraproteinemias
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Parkinson Disease
Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson's Disease.
Regulation of ATP13A2 via PHD2-HIF1? Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
Peripheral Arterial Disease
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease.
Peritonitis
Gordonia species as emerging causes of continuous-ambulatory-peritoneal-dialysis-related peritonitis identified by 16S rRNA and secA1 gene sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS).
Phenylketonurias
A histological study of the hph-1 mouse mutant: an animal model of phenylketonuria and infantile hypertrophic pyloric stenosis.
Anxiety- and depression-like phenotype of hph-1 mice deficient in tetrahydrobiopterin.
Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse.
Impairment of the nitric oxide/cyclic GMP pathway in cerebellar slices prepared from the hph-1 mouse.
Molecular characterization of HPH-1: a mouse mutant deficient in GTP cyclohydrolase I activity.
Neurochemical effects following peripheral administration of tetrahydropterin derivatives to the hph-1 mouse.
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.
Regulation of ?-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin.
Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease.
Tetrahydrobiopterin (BH4) deficiency is associated with augmented inflammation and microvascular degeneration in the retina.
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse.
Tetrahydrobiopterin availability, nitric oxide metabolism and glutathione status in the hph-1 mouse; implications for the pathogenesis and treatment of tetrahydrobiopterin deficiency states.
Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse.
Pneumonia
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: implication in manganese-induced pulmonary inflammation.
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: Implication in manganese-induced pulmonary inflammation.
Pneumonia, Necrotizing
Necrotizing pneumonia and empyema in an immunocompetent patient caused by Nocardia cyriacigeorgica and identified by 16S rRNA and secA1 sequencing.
Polycythemia
Congenital erythrocytosis - discover of a new mutation in the EGLN1 gene.
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
EPAS1 p.M535T mutation in a Bulgarian family with congenital erythrocytosis.
Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience.
Hereditary gene mutations in Korean patients with isolated erythrocytosis.
Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
Loss-of-function zinc finger mutation in the EGLN1 gene associated with erythrocytosis.
Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).
Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.
PHD2 mutation and congenital erythrocytosis with paraganglioma.
Prolyl-4-Hydroxylase 2 Potentially Contributes to Hepatocellular Carcinoma-Associated Erythrocytosis by Maintaining Hepatocyte Nuclear Factor-4? Expression.
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
The Zinc Finger of Prolyl Hydroxylase Domain Protein 2 Is Essential for Efficient Hydroxylation of Hypoxia-Inducible Factor ?.
Pre-Eclampsia
High altitude and pre-eclampsia: Adaptation or protection.
Prostatic Neoplasms
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Pulmonary Disease, Chronic Obstructive
EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population.
Refining susceptibility loci of chronic obstructive pulmonary disease with lung eqtls.
Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2.
Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.
Pulmonary Edema
EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda.
Raised HIF1? during normoxia in high altitude pulmonary edema susceptible non-mountaineers.
Pyloric Stenosis, Hypertrophic
A histological study of the hph-1 mouse mutant: an animal model of phenylketonuria and infantile hypertrophic pyloric stenosis.
Infantile hypertrophic pyloric stenosis (IHPS): a study of its pathophysiology utilizing the newborn hph-1 mouse model of the disease.
Renal Insufficiency
HIF prolyl hydroxylase inhibitors for anemia.
Renal Insufficiency, Chronic
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
Sarcoma
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Stomach Neoplasms
An Insertion/Deletion Polymorphism Within the Proximal Promoter of EGLN2 Is Associated With Susceptibility for Gastric Cancer in the Chinese Population.
Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer.
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
Stroke
HIF prolyl hydroxylase inhibitors for anemia.
HIF-prolyl hydroxylase 2 silencing using siRNA delivered by MRI-visible nanoparticles improves therapy efficacy of transplanted EPCs for ischemic stroke.
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.
Neuronal deficiency of HIF prolyl 4-hydroxylase 2 in mice improves ischemic stroke recovery in an HIF dependent manner.
Thrombosis
Hypoxia and Upregulation of Hypoxia-Inducible Factor 1{alpha} Stimulate Venous Thrombus Recanalization.
Inhibition of prolyl hydroxylase domain proteins selectively enhances venous thrombus neovascularisation.
Triple Negative Breast Neoplasms
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
Tuberculosis
ADP-dependent conformational changes distinguish Mycobacterium tuberculosis SecA2 from SecA1.
ATPase activity of Mycobacterium tuberculosis SecA1 and SecA2 proteins and its importance for SecA2 function in macrophages.
In Vitro Interaction of the Housekeeping SecA1 with the Accessory SecA2 Protein of Mycobacterium tuberculosis.
Label-free Quantitative Proteomics Reveals a Role for the Mycobacterium tuberculosis SecA2 Pathway in Exporting Solute Binding Proteins and Mce Transporters to the Cell Wall.
Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis.
Mycobacterium tuberculosis SatS is a chaperone for the SecA2 protein export pathway.
SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis.
Structural Similarities and Differences between Two Functionally Distinct SecA Proteins, Mycobacterium tuberculosis SecA1 and SecA2.
The Mycobacterium tuberculosis SecA2 System Subverts Phagosome Maturation To Promote Growth in Macrophages.
The SecA2 pathway of Mycobacterium tuberculosis exports effectors that work in concert to arrest phagosome and autophagosome maturation.
The SecA2 secretion factor of Mycobacterium tuberculosis promotes growth in macrophages and inhibits the host immune response.
Tuberculosis, Pulmonary
Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis.
Uterine Neoplasms
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Vascular System Injuries
Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury.
Ventricular Dysfunction
Chronic Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl 4-Hydroxylase Improves Ventricular Performance, Remodeling and Vascularity Following Myocardial Infarction in the Rat.